Introduction

My research aimed to explore innovative therapeutic strategies for Ankylosing Spondylitis (AS), a debilitating autoimmune disease characterized by chronic spinal inflammation and pathological bone formation. While current biologic therapies reduce inflammation, they fall short of regenerating damaged tissue or halting disease progression. In this reflective essay, I outline the decisions I made during the research process—including platform selection, search strategies, and source evaluation—and assesses how critical thinking guided my analysis of regenerative tissue engineering and targeted drug delivery as potential treatment solutions.

Understanding the Research Process

This research was not a traditional literature review in which I analyze studies focused on a single disease or therapy. Instead, my goal was to examine how emerging biomedical technologies—like tissue scaffolds, EVs, and nanomedicine—used in other healthcare setting could be repurposed or re-engineered to treat AS. This type of interdisciplinary inquiry required understanding both the core pathogenesis of AS and how external therapeutic strategies could be adapted to fit those pathological mechanisms.

One of the initial challenges was narrowing my focus. I began by surveying general AS literature to understand the disease holistically. From there, I zoomed in on integral elements of AS pathogenesis—such as cytokine-driven inflammation and abnormal bone formation—that could be targeted with biomedical interventions. I ultimately centered my research around two promising solutions: regenerative tissue engineering and targeted drug delivery.

This approach presented unique difficulties. Since the combination of these technologies for AS treatment is still a new concept, there is limited literature to reference. I bridged the gap by studying how these tools are applied in other diseases and evaluated their theoretical and practical adaptability to AS. In that way, I was not only reviewing exiting answer I was mapping possibilities.

Two key insights emerged from my process:

1. *Organization prevents roadblocks:* Creating a roadmap for refining search terms, organizing citations, and segmenting research by topic area helped prevent the research from becoming overwhelming.

2. *Flexibility drives discovery:* While my initial plan focused on biologics, I pivoted when I found studies on scaffold-drug hybrids such as EV-loaded hydroxyapatite and β-tricalcium phosphate (HA/β-TCP) systems. These hybrid systems offered a more holistic approach and redirected the research toward multimodal therapies with greater therapeutic potential.

The experience reinforced the value of interdisciplinary collaboration, particularly in biomedical research. Blending ideas from immunology, materials science, and bioengineering, gave me the tools to investigate how new therapeutic concepts could meaningfully address underexplored areas of AS treatment.

Decisions on Where to Search

To ensure academic rigor and credibility, I prioritized using comprehensive and peer-reviewed platforms such as Web of Science Core Collection and ProQuest Central, both accessible via Kansas State University's Hale Library subscriptions. These databases provided extensive coverage of literature for both engineering and medical research. I also used open-access resources like PubMed Central to supplement access. The search was further narrowed to studies published in the past ten years to ensure that the literature reflected the latest advancements in cytokine modulation, regenerative medicine, and nanotechnology.

In the early stages of my research, I was introduced to the AI-powered research tool Perplexity by Jason Coleman, an academic services librarian at K-State. He demonstrated how, with thoughtful prompt engineering, large language models can be used to complement traditional search methods. For example, AI goes beyond Boolean filters by recognizing synonyms, keyword variants, and contextual relationships. Perplexity specifically stood out because it generates transparent well-cited answers, guides users toward primary sources, and utilizes customizable search modes an emphasis on accuracy. It proved especially helpful for quickly assessing whether a paper was relevant to my topic, which allowed me to efficiently navigate the broad early stages of research. Jason's guidance made Perplexity an asset in developing an initial understanding of unfamiliar topics and niche healthcare applications.

Strategies for How to Search

My keyword selection was an evolving process. I started broadly with terms such as “AS therapeutics” and “cytokine inhibitors” then gradually refined my search to include more specific phrases like “TNF-α AND bone formation” or “tissue scaffolding AND non-infectious arthritis.” Boolean operators helped narrow search results, and I used filters to exclude older or irrelevant studies.

Using AI also changed how I thought about the research process. I began to view research less as a linear task and more as an interactive, creative process. Instead of relying only on exact keywords or predefined filters, I was able to explore questions more freely and uncover new angles I hadn’t considered. This flexibility helped me become a more thoughtful and strategic researcher.

To stay organized, I used the built in Microsoft Word citation management tool, to catalog sources. Additionally, I maintained a detailed working document to track article relevance, methods and subject focus. I categorized sources based on treatment focus—such as biologics, tissue engineering, or nanomedicine—and disease scope, whether AS-specific or related to broader musculoskeletal disorders. This tagging system enabled quick thematic analysis and comparative review of methodologies.

Source Selection: Balancing Credibility and Innovation

Three key criteria informed source selection:

1. *Credibility*: I relied on peer-reviewed journal articles and reputable scientific publications.
2. *Relevance*: Since many regenerative methods are not AS-specific, I included studies on broader inflammatory conditions like non-infectious arthritis and general musculoskeletal regeneration.
3. *Innovation*: I prioritized papers discussing advanced technologies such as nanoparticle drug carriers, scaffold-based regeneration, and extracellular vesicle (EV) therapies.

I approached conflicting data analytically—for example, studies both supporting and questioning the regenerative abilities of mesenchymal stem cells (MSCs) were examined side-by-side. These conflicts were an opportunity to critically analyze methodology, context, and application, rather than dismissing them. This also helped me appreciate the evolving nature of research in emerging therapeutic fields.

Critical Thinking in Problem-Solving

Several challenges demanded flexible and critical problem-solving:

- Initial searches for “Ankylosing Spondylitis drug delivery” yielded overly broad results. Refining the query to “Stimulus-responsive nanocarriers in spondylarthritis” uncovered more specialized literature.
- Dense technical papers on tissue engineering led me to consult foundational textbooks to better understand complex topics such as “extracellular vesicles”, and “osteogenic potential”.
- When I encountered contrasting views—such as literature praising TNF inhibitors for inflammation control, while others criticized their inability to prevent bone damage—I used these differences to explore combination therapies as a promising direction.

A major turning point came when I discovered that scaffold techniques developed for oral and craniofacial regeneration could potentially be adapted for spinal applications. This insight expanded the scope of my research and required me to think creatively about how to address the biomechanical challenges unique to the lower spine and sacroiliac joints.

In addition to research, I also used AI to support my writing and organization. For example, AI helped me rephrase dense or overly technical sentences, brainstorm transitions between sections, and test how explanations might sound to a general audience. While I wrote the content myself, these tools helped improve clarity and structure throughout the drafting process.

Conclusion

This research journey underscored the essential relationship between structured methodology and adaptive critical thinking. By intentionally selecting credible sources, applying strategic search techniques, and remaining open to evolving directions, the project not only uncovered limitations in current AS treatments but also identified promising paths for innovation. As the demand for regenerative and targeted therapies continues to grow, research processes grounded in rigor and creativity will be critical to shaping the future of patient care.

1701 Platt St
Manhattan, KS 66502

December 12, 2024

Mrs. Erica Simmons
Director of Business Development
BioBridge Collaboratives
2387 George Parks Hwy
Chicago, IL 60605

Dear Erica Simmons,

I am pleased to transmit the completed literature review, titled *Therapeutic Strategies for Ankylosing Spondylitis (AS).* This document aligns with the objectives outlined in the preliminary proposal to provide an in-depth analysis of potential treatment strategies. The review explores recent advancements in mesenchymal stem cell (MSC) therapies, nanomedicine, and tissue engineering, while emphasizing the emerging potential of hybrid strategies that combine extracellular vesicles (EVs) with tissue engineering techniques. These hybrid approaches have the potential to offer comprehensive treatment solutions that address both inflammation and structural damage in AS.

The recommendation is for BioBridge Collaboratives to invest in further development and clinical validation of these hybrid strategies, which could lead to effective, scalable therapies for AS. By advancing these strategies toward approved treatment methods, BioBridge has a unique opportunity to make a significant impact on the quality of life for AS patients.

I trust this report will support BioBridge's in developing cutting-edge medical solutions. Please do not hesitate to reach out for further clarifications or discussions regarding the findings or recommendations.

Sincerely,

Eleanor Braynock

Eleanor Braynock
Biological Systems Engineering Student
Kansas State University
(316)644-7447
ebraynock@gmail.com

Therapeutic Strategies for Ankylosing Spondylitis (AS)

Prepared for

Erica Simmons

Director of Business Development

BioBridge Collaboratives

By

Eleanor K. Braynock

Kansas State University

December 12, 2024

Abstract

Ankylosing Spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, leading to reduced mobility and pain. While current treatments focus on symptom management, they do not halt disease progression or repair tissue damage. Recent advancements in mesenchymal stem cell (MSC) therapies, nanomedicine, and tissue engineering hold transformative potential for addressing the dual challenges of inflammation and tissue regeneration in AS. This paper explores the current landscape of AS therapies, the limitations of existing treatments, and the potential of novel therapeutic strategies to reshape AS treatment. MSC-based therapies and extracellular vesicles (EVs) offer promising strategies for immune modulation and tissue repair, while nanomedicine enables precise drug delivery, and tissue engineering supports structural regeneration. Despite their potential, these therapies face significant challenges, including high costs, scalability, and variability in patient outcomes. Emerging hybrid approaches combining EVs with tissue engineering could provide comprehensive treatment solutions, simultaneously addressing inflammation and structural damage. Further development of these innovations will require multidisciplinary collaboration, robust clinical validation, and strategic investments.

Abbreviations

ADSC – Adipose-derived stem cells
AS – Ankylosing Spondylitis
CAGR – Compound Annual Growth Rate
EV – Extracellular vesicles
MSC – Mesenchymal stem cell
NSAIDS – Non-steroidal anti-inflammatory drugs
TNF-α – Tumor Necrosis Factor
IL-17 – Interleukin-17

Contents

Introduction

Ankylosing Spondylitis (AS) is an inflammatory arthritis primarily affecting the spine and sacroiliac joints. Over time, inflammation causes bones in the spine, called vertebrae, to fuse, resulting in reduced mobility and significant pain. This loss of spinal flexibility can significantly reduce quality of life. AS cannot be cured and presents several areas of growth regarding treatment. Common approaches— anti-inflammatory drugs, lifestyle changes, exercise, and physical therapy—focus on reducing inflammation and managing pain but do not halt disease progression.

Cytokines, proteins involved in immune response, play a significant role in AS progression, leading to both inflammation and abnormal bone formation [1]. This complex intersect contributes to the challenges in treating AS effectively. Tumor Necrosis Factor-α (TNF-α), a type of cytokine, contributes to inflammatory responses and joint damage. While, the majority of contemporary therapeutics have focused on TNF-α, the interleukin-17 (IL-17) also contributes to chronic inflammation and stimulates osteoblast activity leading to excessive bone formation [1] [2]. Understanding these mechanisms provides insights into overcoming the limitations of existing treatments.

Current biologics targeting cytokines often fail to regenerate damaged tissue and significantly compromise patients' autoimmune defense, increasing their risk of infections [1]. This limitation underscores the urgent need for more advanced therapeutic strategies that go beyond symptom management to repair damaged tissues and halt further disease progression. Innovative therapies utilizing mesenchymal stem cells (MSCs) and their derivatives aim to modulate cytokine activity while promoting tissue repair. Similarly, targeted drug delivery therapies aim to precisely direct drugs to diseased tissue, weakening undesirable side effects.

Market Analysis

This market is particularly attractive for product development due to its steady growth and unmet needs in effective and long-lasting AS therapies. The rise in healthcare expenditure, coupled with advancements in biotechnology and nanomedicine, creates fertile ground for innovative solutions. Furthermore, the growing awareness and earlier diagnosis of AS among patients are driving demand for more targeted and regenerative therapies. Companies that invest in addressing these gaps can secure a competitive edge in a market with substantial long-term

potential. The global market for AS therapeutics is projected to grow at a compound annual growth rate (CAGR) of 6.5% from 2023 to 2032, reaching $9.5 billion by 2032. This growth is driven by the increasing prevalence of AS and advancements in therapeutic modalities. North America currently leads the market, accounting for over 43% of global revenue, while Asia-Pacific is expected to exhibit the highest growth rate at 7.1% CAGR [3].

Regenerative Tissue Strategies

Cell-Derived Therapeutics

The development of mesenchymal stem cell (MSC) therapies has gained significant attention due to their comprehensive role in inflammation modulation and tissue regeneration. These stem cells, derived from bone marrow, adipose tissue, and other sources, are characterized by their capacity to differentiate into various cell types, including osteoblasts, chondrocytes, and adipocytes as seen in Figure 1. The potential to address the dual challenges of AS: controlling inflammatory processes and restoring damaged tissues lies in the cells' versatility.



Figure 1. The sources, properties, and applications of mesenchymal stem cells [4].

In the context of AS, MSCs are involved in both disease progression and treatment. MSCs from AS patients behave abnormally, including enhanced osteogenic differentiation often leading to excessive bone formation. However, therapeutic applications of MSCs leverage their immunosuppressive and reparative properties. MSC infusions have demonstrated the ability to mitigate inflammatory responses by interacting with T cells, B cells, and cytokine networks, thereby reducing the severity of disease symptoms [4]. Understanding the molecular mechanisms driving these contrasting roles is crucial for optimizing MSC-based interventions.

Cell-based therapies for AS leverage the regenerative capabilities of MSCs and adipose-derived stem cells (ADSCs). These therapies have shown promising capabilities to repair damaged tissues within the spine, reduce immune-mediated inflammation, and slow the progression of the disease [5]. MSCs and ADSCs are particularly valued for their ability to secrete bioactive factors, such as growth factors and cytokines, that promote tissue regeneration and modulate immune responses. Recent studies have explored combining these cells with biomaterials, such as hydrogels or decellularized matrices, to enhance their viability and functionality during transplantation. Such approaches aim to overcome the challenges of cell survival and integration in the harsh inflammatory climate of AS [6].

Limitations - Cell-Derived Therapeutics

Cell-based therapies face challenges such as ensuring the survival and integration of transplanted cells, managing immune rejection, and achieving consistent therapeutic outcomes. Additionally, the cost of harvesting, expanding, and delivering these cells remains high. MSC therapies face several challenges, including high production costs, variability in patient response, and potential risks of immune rejection. Additionally, the long-term efficacy and safety of MSC-based treatments remain under investigation.

Extracellular Vesicles (EVs) from MSCs

Recent research emphasizes the potential of extracellular vesicles (EVs) derived from MSCs as a cell-free therapeutic strategy. These vesicles, encompassing exosomes, serve as carriers of bioactive molecules such as proteins, lipids, and nucleic acids, including microRNAs. By modulating the behavior of immune cells, EVs contribute to the resolution of inflammation and support tissue repair. For instance, specific microRNAs within EVs have been shown to

downregulate pro-inflammatory cytokines like TNF-α and IL-17 and MSC-derived exosomes have demonstrated regenerative capabilities comparable to MSCs. Additionally, the scalable nature of EV production addresses logistical challenges associated with cell-based therapies, making them a promising alternative [4] [7]. These EVs replicate MSC effects by regulating immunological processes, remodeling tissues, and maintaining cellular homeostasis. The biological efficacy of EVs largely depends on their cargo, particularly microRNAs, which modulate critical pathways in AS pathogenesis. EV-based therapies offer a safer and more scalable alternative to MSC transplantation [4].

Limitations - Extracellular Vesicles (EVs) from MSCs

EV-based therapies are limited by the need for standardization in production and characterization processes. Moreover, the long-term biological impacts and potential off-target effects of EVs require thorough investigation.

Tissue Engineering

Biomaterials play a vital role in supporting cell-based therapies by providing structural support and promoting tissue growth. Specifically, scaffolds serve as a temporary framework, guiding cell differentiation and tissue repair processes. Hydroxyapatite and β-tricalcium phosphate (HA/β-TCP) scaffolds are potential candidates for oral and facial bone regeneration and have been used as culture systems in vitro to simulate bone microenvironment for AS treatment. However, concerns with the low tensile strength and toughness of the material would make them susceptible to fractures in weight-bearing areas such as the spine [8]. Integrating biomaterials with MSC therapy has been shown to enhance regenerative outcomes in musculoskeletal disorders [6].

Limitations – Tissue Engineering

Unlike other bone regeneration for other areas, the lower spine and sacroiliac joints are significantly weight bearing and involved in everyday actions such as standing, walking, and sitting. Through further research and development, scaffolds can be engineered to withstand mechanical demands and support effective tissue regeneration and integration. Developing biocompatible scaffolds that effectively integrate with host tissue remains a significant challenge.

These scaffolds must not only provide temporary mechanical support but also create an environment conducive to cell attachment, proliferation, and differentiation. Additionally, scaling up production for widespread clinical application requires further innovation.

Targeted Drug Delivery

Nanoparticle Systems

Nanoparticle systems have revolutionized drug delivery and therapeutics in healthcare, offering unprecedented precision and efficacy in treating various diseases. These microscopic carriers, typically ranging from 1 to 100 nanometers in diameter, provide numerous advantages over conventional drug delivery methods [7]. Nanoparticles enhance drug bioavailability, enable targeted delivery to specific cells or tissues, and allow for controlled release of therapeutic agents. While nanoparticle systems have been FDA-approved for various cancers, infectious diseases, and neurological disorders. There has been limited clinical approval for osteoarthritis.

Regarding AS treatment, nanomedicine enhances drug efficacy while reducing systemic side effects. Liposomes, polymeric nanoparticles, and hydrogels have been developed for improved drug retention and specificity. For example, nanocurcumin, developed from turmeric molecules, has shown potential in preventing the production of IL-17 cytokines, a critical player in AS pathology [9]. Additionally, nonsteroidal anti-inflammatory drugs (NSAIDs) loaded with nanocarriers exhibited substantial improvements in targeting efficiency, therapeutic efficacy, and reduction in side effects [7].

Limitations – Nanoparticle Systems

Despite promising preclinical results, significant challenges remain before clinical approval can be achieved. Issues such as the potential toxicity of nanoparticles and difficulties in scaling up manufacturing processes present substantial obstacles. Furthermore, navigating the intricate and often protracted regulatory pathways for nanomedicine-based therapies adds another layer of complexity to their development and implementation.

Stimulus-Responsive Nanocarriers

An innovative aspect of nanomedicine involves the design of stimuli-responsive nanocarriers, which release therapeutic agents upon encountering specific physiological triggers. For AS, this includes pH-sensitive nanocarriers that release drugs in the acidic microenvironment of inflamed tissues or enzyme-sensitive systems that respond to proteases present at disease sites. These adaptive mechanisms ensure that anti-inflammatory agents, such as NSAIDs or biologics, are delivered directly to affected regions, maximizing efficacy while reducing systemic exposure. This precise targeting capability not only minimizes side effects but also enhances the therapeutic index of existing drugs [7].

Limitations – Stimulus-Responsive Nanocarriers

These systems often involve complex, expensive designs, with sophisticated materials and manufacturing processes that increase costs and pose scalability challenges. Clinical trials validating their safety and efficacy are limited, and variability in patient response due to the heterogeneous nature of AS further complicates their effectiveness. Furthermore, while these systems can offer targeted therapeutic responses, their regenerative capacity is often limited, making them less suitable for addressing the tissue damage typical in AS.

Conclusion

Recent advancements in mesenchymal stem cell (MSC) therapies, nanomedicine, and tissue engineering offer transformative potential for the treatment of Ankylosing Spondylitis (AS). As summarized in Table 1, each approach presents unique advantages: MSC-based therapies and extracellular vesicles (EVs) target immune modulation and tissue repair, nanomedicine provides precision in drug delivery, and tissue engineering supports structural regeneration. However, significant limitations such as cost, scalability, and variability in patient outcomes must be addressed. Despite these limitations, these technologies present significant opportunities to reshape AS treatment protocols and improve long-term patient outcomes.

Table 1. Summary of therapeutic strategies' advantages and limitations

Therapeutic Strategy	Mechanism	Advantages	Limitations
Mesenchymal Stem Cell (MSC) Therapy	Immunomodulation, tissue regeneration	Promotes anti-inflammatory effects; potential for tissue repair;	High cost; variability in patient response; risk of immune rejection
Extracellular Vesicles (EVs)	Delivery of bioactive molecules (e.g., microRNAs, proteins)	Scalable; avoids complications of cell-based therapy; precise modulation of immune responses	Limited targeting specificity; limited research on long-term effects
Nanoparticle Drug Delivery	Targeted delivery of anti-inflammatory agents or biologics	Reduces side effects; increases drug retention and efficacy	Potential toxicity of nanoparticles; large-scale manufacturing challenges
Stimuli-Responsive Nanocarriers	Drug release triggered by environmental changes (e.g., pH, enzymes)	Precise targeting; minimizes off-target effects; improves therapeutic index	Complex design; high development cost; limited clinical trials
Tissue Engineering (Scaffolds)	Structural support for cell growth and tissue repair	Enhances cell therapy efficacy; potential for spinal regeneration	Requires biocompatible materials; integration with host tissue; immune reaction

Recommendations

Emerging hybrid strategies that combine cell-derived extracellular vesicles (EVs) with tissue engineering techniques hold significant potential in providing comprehensive treatment solutions for AS, addressing both inflammation and structural damage. The continued development of these innovations necessitates interdisciplinary collaboration, rigorous clinical validation, and strategic investments. Additionally, addressing challenges such as scalability, manufacturing processes, and variability in patient responses will be key to success.

It is recommended that BioBridge Collaboratives prioritize the further development and clinical validation of these hybrid strategies. Engaging in partnerships with academic institutions,

research organizations, and other industry leaders will facilitate knowledge exchange and accelerate progress. Furthermore, planning for regulatory approval early in the process will ensure that these therapies meet the necessary health and safety standards. By advancing these strategies toward approved treatment methods, BioBridge has a unique opportunity to develop effective, scalable therapies that can make a substantial impact on the quality of life for AS patients.

References

[1] J. Fletcher, "How do Biologics for Ankylosing Spondylitis Work?," Medical News Today, 10 April 2024. [Online]. Available: https://www.medicalnewstoday.com/articles/biologics-for-ankylosing-spondylitis. [Accessed October 2024].

[2] C. Felice, A. D. Buono, R. Gabbidadini, M. Rattazzi and A. Armuzzi, "Cytokines in Spondyloarthritis and Inflammatory Bowel Diseases: From Pathogenesis to Therapeutic Implications," *International Journal of Molecular Sciences,* vol. 24, no. 4, p. 3957, 2023.

[3] Acumen Research and Consulting, "Ankylosing Spondylitis Market Size - Global Industry, Share, Analysis, Trends and Forecast 2023 - 2032," Pashan, India, 2023.

[4] F. Tavasolian and R. D. Inman, "Biology and Therapeutic Potential of Mesenchymal Stem Cell Extracellular Vesicles in Axial Spondyloarthritis," *Communications Biology,* vol. 6, p. 413, 2023.

[5] D. Shen, Z. Wang, H. Wang, H. Zhu, C. Jiang, F. Xie, H. Zhang, Q. Lv, Q. Liu and H. Wang, "Evaluation of Preclinical Efficacy of Human Umbilical Cord Mesenchymal Stem Cells in Ankylosing Spondylitis," *Frontiers in Immunology,* vol. 14, 2023.

[6] S. Park, K. A. Rahaman, Y.-C. Kim, H. Jeon and H.-S. Han, "Fostering Tissue Engineering and Regenerative Medicine to Treat Musculoskeletal Disorders in Bone and Muscle," *Bioactive Materials,* vol. 40, pp. 345-365, 2024.

[7] L. Chen, Y. Wang, L. Sun, J. Yan and H.-Q. Mao, "Nanomedicine Strategies for Anti-Inflammatory Treatment of Noninfectious Arthritis," *Advanced Healthcare Materials,* vol. 10, no. 11, 2021.

[8] G. Zheng, Z. Xie, P. Wang, J. Li, M. Li, S. Cen, S. Tang, W. Liu, G. Ye, Y. Li, S. Wang, X. Wu, H. Su, Y. Wu and H. Shen, "Enhanced Osteogenic Differentiation of Mesenchymal Stem Cells in Ankylosing Spondylitis: a Study Based on a Three-dimensional Biomimetic Environment," *Cell Death & Disease,* vol. 10, no. 5, pp. 1-11, 2019.

[9] Y. e. a. Xi, "Advances in Nanomedicine for the Treatment of Ankylosing Spondylitis," *International Journal of Nanomedicine,* vol. 14, p. 8521, 2019.